GILD stock verdict - Avoid
GILD
GILEAD SCIENCES, INC.
AVOIDHealthcare
$150.93
Fundamentals below bar
$150.93
Heavy$82.06Buy$109.42Fair$136.77Exit$164.12
VALUE53
GROWTH27
QUALITY100
TECHNICAL—
TRUST SCORE
83High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Balance sheet holds net cash (cash exceeds total debt)
CONS
- Not yet profitable on trailing twelve-month earnings
- High leverage — debt-to-equity of 2.22
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on GILD. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is GILD rated Avoid?
GILD (GILEAD SCIENCES, INC.) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Balance sheet holds net cash (cash exceeds total debt)
Is GILD overvalued right now?
GILD is trading at $150.93 versus an estimated fair value of $136.77. That puts the stock in avoid territory on this framework. Not yet profitable on trailing twelve-month earnings and High leverage — debt-to-equity of 2.22
What should I watch before acting on GILD?
Watch the trust score of 83, the earnings-quality checks, and any red flags. Not yet profitable on trailing twelve-month earnings and High leverage — debt-to-equity of 2.22